Prazosin
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Prazosin
Prazosin: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Prazosin, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own known uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| hypertension |
| hypertensive disorder |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13367M | APO-Prazosin | Tablet 5 mg (as hydrochloride) | Valid |
Safety Considerations
- Disease contraindication signals (knowledge graph, not label text): chronic kidney disease, chronic renal failure, end-stage renal failure, intraoperative floppy iris syndrome, narcolepsy, narcolepsy-cataplexy syndrome, central nervous system disease, Balo concentric sclerosis, X-linked adrenoleukodystrophy. These come from a knowledge graph and should be verified against the label. The renal signals are particularly relevant to a kidney-related indication.
- Drug Interactions: 77 interactions were identified. Those shown are mostly Moderate severity:
- Corticosteroids (hydrocortisone, prednisolone, prednisone, dexamethasone, betamethasone, budesonide, triamcinolone)
- Opioids (morphine, liposomal morphine, opium)
- SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)
- Cannabinoids (dronabinol, nabilone)
- Bupropion and acetylsalicylic acid
- Pantoprazole and metformin are listed with unknown severity.
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.